Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, res...
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
...
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03915405
- Locations
- 🇺🇸
Kyowa Research Site USA005, Iowa City, Iowa, United States
🇺🇸Kyowa Research Site USA 009, Houston, Texas, United States
🇪🇸Kyowa Research Site ESP003, Barcelona, Spain
AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma
- Conditions
- Interventions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- German Cancer Research Center
- Target Recruit Count
- 60
- Registration Number
- NCT03893903
- Locations
- 🇩🇪
Charité Berlin, Neurosurgery, Berlin, Germany
🇩🇪University Hospital Frankfurt, Neurooncology, Frankfurt/Main, Germany
🇩🇪University Hospital Dresden, Neurosurgery, Dresden, Germany
Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 18
- Registration Number
- NCT03892642
- Locations
- 🇺🇸
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study
- Conditions
- Interventions
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 67
- Registration Number
- NCT03891238
- Locations
- 🇮🇹
Istituto Europeo di Oncologia, Milano, Italy
🇮🇹Fondazione Salvatore Maugeri, Pavia, Italy
🇮🇹Arcispedale Santa Maria Nuova Di Reggio Emilia, Reggio Emilia, Italy
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Leap Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03861403
- Locations
- 🇺🇸
Horizon Oncology Research, Lafayette, Indiana, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Immunotherapy In Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 101
- Registration Number
- NCT03854799
- Locations
- 🇮🇹
Policlinico Gemelli, Rome, Italy
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 325
- Registration Number
- NCT03845166
- Locations
- 🇺🇸
Exelixis Clinical Site #84, Los Angeles, California, United States
🇺🇸Exelixis Clinical Site #71, Stanford, California, United States
🇺🇸Exelixis Clinical Site #85, Bronx, New York, United States
Targeting the Tumor Microenvironment in R/M SCCHN
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 71
- Registration Number
- NCT03844763
- Locations
- 🇮🇹
AO Santa Croce e Carle di Cuneo, Cuneo, Italia/cuneo, Italy
🇮🇹Azienda Ospedaliera S. Croce E Carle Di Cuneo - Cuneo (Cn) Oncologia Medica, Cuneo, Italy
Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 30
- Registration Number
- NCT03827044
- Locations
- 🇬🇧
Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 23
- Registration Number
- NCT03826589
- Locations
- 🇭🇰
The University of Hong Kong, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.